[First use of CRISPR for gene therapy]

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Cancer immunotherapy aims to harness the immune system to fight tumors.
• Immune checkpoints, like PD-1, can suppress anti-tumor immune responses.
• CRISPR gene editing offers a precise tool for genetic modification.

Purpose of the Study:

• To initiate clinical trials using CRISPR technology for cancer treatment.
• To engineer T cells by inactivating the PD-1 gene to enhance anti-tumor immunity.

Main Methods:

• Utilizing CRISPR-Cas9 gene editing technology.
• Modifying T cells ex vivo to disable the gene encoding PD-1.
• Administering engineered T cells to cancer patients in a clinical trial setting.

Main Results:

• Two clinical trials are nearing commencement, one in the USA and one in China.
• The Chinese trial may begin sooner due to expedited regulatory approval.
• Potential for serious autoimmune reactions is a significant concern.

Conclusions:

• CRISPR-based T cell engineering targeting PD-1 is advancing into clinical trials.
• Early initiation of trials, particularly in China, is noted.
• The risk of severe autoimmune side effects necessitates careful monitoring and management.